Agreements reached under this partnership
Capital and Business Alliance- 1
Development of drugs for acute spinal cord injury treatment and vocal fold scar treatment
- 2
Manufacturing of drugs for acute spinal cord injury treatment and vocal fold scar treatment
- 3
Regulatory approval for drugs for acute spinal cord injury treatment and vocal fold scar treatment
- 4
Launch preparations for drugs for acute spinal cord injury treatment and vocal fold scar treatment
- 5
Sales of drugs for acute spinal cord injury treatment and vocal fold scar treatment
- 6
Provision of information on drugs for acute spinal cord injury treatment and vocal fold scar treatment
These are items that the documents state the two companies will work on. The lines above and below represent arrangements between the two companies.
This indicates whether the companies will do more than work together, such as holding each other’s shares or seconding personnel (capital and business alliance).
| Item | Details |
|---|---|
| Name of alliance partner | 丸石製薬株式会社 |
| Alliance partner's business activities | The company’s business is built on the fields of perioperative medicine, infection control and basic drugs, and it is also expanding into acute and emergency medicine and supportive care, including cancer supportive care. It conducts broad-ranging research, development and dissemination of pharmaceuticals. |
| Alliance partner's location | Osaka City, Osaka Prefecture |
| Type of alliance | Capital and Business Alliance |
| Details of the alliance | Development of drugs for acute spinal cord injury treatment and vocal fold scar treatment, Manufacturing of drugs for acute spinal cord injury treatment and vocal fold scar treatment, Regulatory approval for drugs for acute spinal cord injury treatment and vocal fold scar treatment, Launch preparations for drugs for acute spinal cord injury treatment and vocal fold scar treatment, Sales of drugs for acute spinal cord injury treatment and vocal fold scar treatment, Provision of information on drugs for acute spinal cord injury treatment and vocal fold scar treatment |
| Number of shares acquired | To be finalized on the date the terms are determined |
| Acquisition price | ¥300 million |
| Shareholding Policy | Planned for medium- to long-term ownership |
| Share Acquisition Date and Payment Date | 7 December 2026 (予定) |
Items this document does not state (14)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To further strengthen the business relationship between the two companies through capital ties and further advance collaboration, leveraging their respective expertise in the development, manufacturing, regulatory approval, launch preparations, sales and provision of information for drugs for acute spinal cord injury treatment and vocal fold scar treatment.